Long-term Preventive Use of Esperoct Effective in Hemophilia A

Long-term Preventive Use of Esperoct Effective in Hemophilia A

309412

Long-term Preventive Use of Esperoct Effective in Hemophilia A

Long-term prophylactic (preventive) treatment with a fixed dose of Esperoct (turoctocog alfa pegol) — approved in the U.S. and the EU in 2019 — was effective in preventing and stopping bleeding in people with severe hemophilia A, according to data from two Phase 3 clinical trials. Findings from the two studies also showed that, over a period of up to five years, there were fewer bleeds, and those reoccurred less frequently. “Fixed-dose … prophylaxis demonstrated…

You must be logged in to read/download the full post.